52,000-square-foot corporate headquarters in San Diego with R&D and GMP manufacturing center Builds on current capability at Artiva’s partner, GC Cell’s facility in Republic of Korea Custom-built GMP manufacturing center further enables Artiva’s leadership position in scaled, off-the-shelf NK and CAR-NK therapeutic manufacturing for treatment of solid and hematological cancers SAN DIEGO, June 13, 2022…
SAN DIEGO, June 6, 2022 – Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer (NK) cell therapies that are safe and accessible to cancer patients, today announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer. As a highly respected drug development leader, Dr….